The clinical fallout of organizational resilience in oncology during the pandemic.

Competing Interests: Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://med.amegroups.com/article/view/10.21037/med-21-34/coif). The series “Changes in Management of Mediastinal Tumours Following the Surge of COVID-19 Pandemic” was commissioned by the editorial office without any funding or sponsorship. GLB and AA served as the unpaid Guest Editors of the series. GLB serves as an unpaid editorial board member of Mediastinum from September 2020 to August 2022. GLB reports consulting fee from AstraZeneca and Roche, Support for attending meetings and/or travel form AstraZeneca and Ipsen. AA reports personal fees from AstraZeneca, Pfizer, Takeda, Roche, Takeda, MSB, and BMS, as well as grants and personal fees from Boehringer-Ingelheim, outside the submitted work. The authors have no other conflicts of interest to declare.